Abstract Library

#2984 AGTR1 Is Overexpressed in Neuroendocrine Neoplasms, Regulates Secretion and May Serve as a Target for Molecular Imaging and Therapy

Introduction: Peptide receptor targeting has proven to be a pivotal tool for diagnostic imaging and radioligand therapy of neuroendocrine neoplasms (NENs), which frequently express somatostatin receptors (SSTRs) on their cell surface. However, up to 30 % of NEN patients do not benefit from SSTR-based approaches, others develop a resistance.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Grötzinger C, Exner S, Schuldt C, Du J, Sachindra S,

Keywords: receptor, targeting, imaging, prrt, peptide, angiotensin,

#2294 Identification and Validation of the Angiotensin II Receptor Type 1 as a Possible Anti-Cancer Target in Neuroendocrine Tumors

Introduction: Neuroendocrine tumours (NETs) have been found to overexpress somatostatin receptors (SSTRs), which led to the development of somatostatin analogs utilized for diagnostics and therapeutics. However, around 30% of all NETs do not respond to somatostatin based approaches, leading to an interest to find and characterize alternative cell surface targets.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Grötzinger C

Authors: Grötzinger C, Exner S, Wiedenmann B,

Keywords: AGTR1, PRRT, autoradiography, radioligand binding assay,

#2291 Somatostatin Analogs and mTOR Inhibitors as Radioprotectors or Radiosensitizers in Neuroendocrine Tumor Cells

Introduction: Neuroendocrine tumors (NETs) express somatostatin receptors that are currently utilized for diagnostic and therapeutic approaches. For peptide receptor radionuclide therapy (PRRT), somatostatin analogs are coupled to radionuclides like 90Y or 177Lu, which after injection are bound and taken up specifically by NETs. One hypothesis potentially explaining the discrepancies between expected result and observed outcome of PRRT might be that somatostatin analogs induce a G1 arrest in NET cells, thereby rendering them radioresistant.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Grötzinger C

Authors: Grötzinger C, Exner S, Prasad V, Erdmann S, Wiedenmann B,

Keywords: PRRT,

#2280 The BON-SSTR2 Chicken Chorioallantoic Membrane (CAM) Model for the Analysis of Lu-17-DOTATOC Sensitizing Agents

Introduction: Peptide radioreceptor therapy (PRRT) is a promising therapy option for SSTR2-positive pancreatic neuroendocrine neoplasms (NEN). However, therapeutic effects are often not satisfying concerning sensitivity to PRRT. We hypothesize that the slow proliferation of NENs provides sufficient time for the repair of beta-particle induced-DNA damage. The ubiquitin-proteasome-system is involved in DNA damage repair and affected by the proteasome inhibitor bortezomib (Velcade®). The inhibition of DNA damage repair during PRRT may be an option to improve therapy response in NEN. We have recently demonstrated the damage repair inhibitory and pro-apoptotic effect of bortezomib in NEN in vitro (Briest et al., in revision).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Briest F

Authors: Briest F, Grötzinger C, Exner S, Sedding D, Baum R,

Keywords: peptide radioreceptor therapy, Lu-177-DOTATOC, PRRT, bortezomib, in vivo model, SPECT/CT Imaging, chicken CAM model, Sensitizer, DNA damage repair,

#2259 Clinical Characteristics, Treatment Outcomes and Potential Novel Therapeutic Options for Patients with Prostatic Neuroendocrine Carcinoma

Introduction: Prostatic neuroendocrine carcinomas (PNECs) are rare tumors with poor prognosis. While platinum and etoposide based chemotherapy regimens (PE) are commonly applied in first-line for advanced disease, clinical-grade evidence for treatment options in second-line and beyond is very limited.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Apostolidis L, Nientiedt C, Winkler E, Stenzinger A, Duensing S,

Keywords: neuroendocrine carcinoma, prostate, chemotherapy, immunotherapy,